Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human VIR-5500 in prostate cancer
jRCT2031260590Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of SAR446329 in prostate cancer (PCa) (12 arms), sponsored by Astellas Pharma. Started Oct 2026; status: recruiting.
02
Drugs
SAR446329
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031260590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260590.